JP2010528091A - ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 - Google Patents

ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 Download PDF

Info

Publication number
JP2010528091A
JP2010528091A JP2010509824A JP2010509824A JP2010528091A JP 2010528091 A JP2010528091 A JP 2010528091A JP 2010509824 A JP2010509824 A JP 2010509824A JP 2010509824 A JP2010509824 A JP 2010509824A JP 2010528091 A JP2010528091 A JP 2010528091A
Authority
JP
Japan
Prior art keywords
cancer
vinflunine
trastuzumab
weeks
neoplasm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010509824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010528091A5 (enExample
Inventor
バール、バンホベル
マリー‐クレール、ピネル
フランソワ‐ミシェル、デルガド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38353425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010528091(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2010528091A publication Critical patent/JP2010528091A/ja
Publication of JP2010528091A5 publication Critical patent/JP2010528091A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2010509824A 2007-05-31 2008-05-29 ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法 Withdrawn JP2010528091A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07290679A EP1997534A1 (en) 2007-05-31 2007-05-31 Cancer treatment combination therapy comprising vinflunine and trastuzumab
PCT/EP2008/056620 WO2008145697A1 (en) 2007-05-31 2008-05-29 Cancer treatment combination therapy comprising vinflunine and trastuzumab

Publications (2)

Publication Number Publication Date
JP2010528091A true JP2010528091A (ja) 2010-08-19
JP2010528091A5 JP2010528091A5 (enExample) 2011-07-14

Family

ID=38353425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010509824A Withdrawn JP2010528091A (ja) 2007-05-31 2008-05-29 ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法

Country Status (18)

Country Link
US (1) US20100196363A1 (enExample)
EP (2) EP1997534A1 (enExample)
JP (1) JP2010528091A (enExample)
KR (1) KR20100017752A (enExample)
CN (1) CN101687104A (enExample)
AR (1) AR066778A1 (enExample)
AU (1) AU2008257555A1 (enExample)
BR (1) BRPI0812280A2 (enExample)
CA (1) CA2689664A1 (enExample)
CL (1) CL2008001589A1 (enExample)
IL (1) IL202393A0 (enExample)
MX (1) MX2009012874A (enExample)
NO (1) NO20093536L (enExample)
RU (1) RU2009146882A (enExample)
TN (1) TN2009000490A1 (enExample)
TW (1) TW200908976A (enExample)
WO (1) WO2008145697A1 (enExample)
ZA (1) ZA200908247B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
PL4234033T3 (pl) 2011-10-14 2025-04-28 F. Hoffmann-La Roche Ag Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2
EP3800204A1 (en) 2013-04-16 2021-04-07 F. Hoffmann-La Roche AG Pertuzumab variants and evaluation thereof
EP3481422A1 (en) * 2016-07-06 2019-05-15 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
CR20190376A (es) 2017-01-17 2019-11-20 Genentech Inc Formulaciones de anticuerpos de her2 subcutáneas
KR20190096384A (ko) 2017-03-02 2019-08-19 제넨테크, 인크. Her2-양성 유방암 어쥬번트 치료
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation

Also Published As

Publication number Publication date
NO20093536L (no) 2009-12-16
WO2008145697A1 (en) 2008-12-04
IL202393A0 (en) 2010-06-30
AR066778A1 (es) 2009-09-09
MX2009012874A (es) 2010-03-31
EP2164573A1 (en) 2010-03-24
TW200908976A (en) 2009-03-01
AU2008257555A1 (en) 2008-12-04
KR20100017752A (ko) 2010-02-16
ZA200908247B (en) 2010-10-27
CA2689664A1 (en) 2008-12-04
US20100196363A1 (en) 2010-08-05
TN2009000490A1 (en) 2011-03-31
EP1997534A1 (en) 2008-12-03
CN101687104A (zh) 2010-03-31
BRPI0812280A2 (pt) 2014-11-18
CL2008001589A1 (es) 2009-03-06
RU2009146882A (ru) 2011-07-10

Similar Documents

Publication Publication Date Title
JP2010528091A (ja) ビンフルニンおよびトラスツズマブを含んでなる癌治療の組合せ療法
US10478428B2 (en) Combination therapy for cancer treatment
EP3342411B1 (en) Rapamycin derivative for treating pancreas cancer
US10238630B2 (en) Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
JP2022017295A (ja) Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法
KR20170131491A (ko) Ras 돌연변이와 관련된 암의 치료 방법
CN107921005A (zh) 利用纳米颗粒治疗肿瘤的组合物和方法
Kelley et al. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206
EP4659741A1 (en) Use of paclitaxel cationic liposome in treating tumors
AU2018234141A1 (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
Patnaik et al. ENZ-2208, a novel anticancer agent, in patients with advanced malignancies: a phase 1 dose-escalation study
HK1139345A (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
JP2009509974A (ja) 抗癌治療
HK40122790A (zh) 治疗癌症的方法和用途
HK1257249B (en) Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
JP2010111582A (ja) リファンピシンを成分とする肝臓癌治療剤
HK1232469B (en) Rapamycin derivative for the treatment of lung cancer
HK1146245B (en) Treatment of solid kidney tumours with a rapamycin derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110526

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111019